Drug Profile
Research programme: infectious diseases therapeutics - Plex Pharmaceuticals
Latest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Plex Pharmaceuticals
- Class Antivirals; Small molecules
- Mechanism of Action Peptide hydrolase inhibitors; Viral nonstructural protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Conjunctivitis
- No development reported Dengue; West Nile virus infections; Zika virus infection
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for preclinical development in Dengue in USA
- 28 Jan 2024 No recent reports of development identified for preclinical development in West Nile virus infections in USA
- 28 Jan 2024 No recent reports of development identified for preclinical development in Zika-virus-infection in USA